About Alpha-2-macroglobulin receptor-associated protein
Alpha-2-macroglobulin receptor-associated protein (LRPAP1) is a protein
from Homo sapiens identified by UniProt accession
P30533, 357 residues long.
MolForge cross-references it against 0 known binders and
262 disease associations.
Target properties
| Protein name | Alpha-2-macroglobulin receptor-associated protein |
| UniProt accession | P30533 |
| Gene | LRPAP1 |
| Organism | Homo sapiens |
| Length | 357 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (262)
Diseases linked to this target (Open Targets).
- Rare isolated myopia · score 0.64
- arterial stiffness measurement · score 0.26
- forced expiratory volume · score 0.24
- vital capacity · score 0.23
- Cleft palate · score 0.22
- low density lipoprotein cholesterol measurement · score 0.15
- sex hormone-binding globulin measurement · score 0.11
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- prostate cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30533-F1 | alphafold | PREDICTED | 75.16 | — |
Amino-acid sequence (357 residues)
MAPRRVRSFL RGLPALLLLL LFLGPWPAAS HGGKYSREKN QPKPSPKRES GEEFRMEKLN QLWEKAQRLH LPPVRLAELH ADLKIQERDE LAWKKLKLDG LDEDGEKEAR LIRNLNVILA KYGLDGKKDA RQVTSNSLSG TQEDGLDDPR LEKLWHKAKT SGKFSGEELD KLWREFLHHK EKVHEYNVLL ETLSRTEEIH ENVISPSDLS DIKGSVLHSR HTELKEKLRS INQGLDRLRR VSHQGYSTEA EFEEPRVIDL WDLAQSANLT DKELEAFREE LKHFEAKIEK HNHYQKQLEI AHEKLRHAES VGDGERVSRS REKHALLEGR TKELGYTVKK HLQDLSGRIS RARHNEL
Explore Alpha-2-macroglobulin receptor-associated protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets